ImmunoPrecise Antibodies

Company Description

ImmunoPrecise Antibodies Ltd. is a biotherapeutic research company. It is advancing Bio-Native AI at the intersection of biology and computation. Its LENSai and HYFT platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. The core of its operations encompasses a diverse suite of proprietary technologies that aid in the exploration, discovery, and development of novel drugs and biologics. Integrated within its wet lab infrastructure is a diverse array of in silico technologies. As an end-to-end service provider of antibody discovery and development, its computational methodologies allow the Company to perform detailed and comprehensive evaluations across various stages of biologic discovery and development. It is involved in antibody characterization studies, which encompass affinity measurements, epitope landscape profiling, and others.

Analysis

ANALYSIS: With an Obermatt 360° View of 94 (better than 94% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock ImmunoPrecise Antibodies are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for ImmunoPrecise Antibodies. The consolidated Growth Rank has a good rank of 89, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 89% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 53, which means that professional investors are more optimistic about the stock than for 53% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 32, which means that the share price of ImmunoPrecise Antibodies is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 68% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 39, which means that the company has a financing structure that is riskier than those of 61% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

Country

Canada

Industry Life Sciences Tools & Services

Size X-Small

Website immunoprecise.com

Index

NASDAQ

Add to Watchlist

See Similar Stocks

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.